6-diazo-5-oxo-L-nor-Leucine (Synonyms: DON, NSC 7365) |
Catalog No.GC41224 |
La 6-Diazo-5-oxo-L-nor-Leucine (DON) est un analogue de la glutamine qui inhibe les glutaminases, un inactivateur sélectif et basé sur le mécanisme des enzymes utilisant la glutamine[1-3].
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 157-03-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
MC38 cells |
Preparation Method |
Tumor cells treated with increasing concentrations of 6-Diazo-5-oxo-L-nor-Leucine for 48h. |
Reaction Conditions |
10-2µM-102µM ;48h |
Applications |
6-Diazo-5-oxo-L-nor-Leucine inhibited cell proliferation, and the inhibitory effect increased with the increase of concentration. |
Animal experiment [2]: | |
Animal models |
Female athymic nude (nu/J) mice (pancreatic cancer cells S2VP10) |
Preparation Method |
The tumors reached a size of 100 mm and were given to 6-Diazo-5-oxo-L-nor-Leucine at the end of the 4th week, and the mice were killed. |
Dosage form |
1 mg/kg;5 days a week |
Applications |
Treatment with 6-Diazo-5-oxo-L-nor-Leucine decreased tumor progression as well as end-of-study tumor weight and volume. |
References: [1]. Leone RD, Zhao L, et,al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019 Nov 22;366(6468):1013-1021. doi: 10.1126/science.aav2588. Epub 2019 Nov 7. PMID: 31699883; PMCID: PMC7023461. |
La 6-Diazo-5-oxo-L-nor-Leucine (DON) est un analogue de la glutamine qui inhibe les glutaminases, un inactivateur sélectif et basé sur le mécanisme des enzymes utilisant la glutamine[1-3].
La 6-Diazo-5-oxo-L-nor-Leucine (10-2µM-102µM ;48h) a inhibé la prolifération cellulaire, et l'effet inhibiteur a augmenté avec l'augmentation de la concentration[4]. La 6-Diazo-5-oxo-L-nor-Leucine (0,3 mM; 1 h) a inhibé le catabolisme de la glutamine dans les cellules WI-L2[1]. Le traitement avec la 6-Diazo-5-oxo-L-nor-Leucine à 50 µM a diminué la formation de colonies dans les cellules S2VP10[5].
La L-nor-leucine 6-diazo-5-oxo (1 mg/kg ; 5 jours par semaine) a réduit la progression tumorale ainsi que le poids et le volume de la tumeur à la fin de l'étude[6]. En tant qu'inhibiteur de la glutaminase (GLS), elle produit un soulagement durable de la douleur lorsqu'elle est appliquée sur la patte enflammée des rats arthritiques. Le DOX (2 mM, 0,05 ml ; 2 fois) peut réduire l'augmentation des transporteurs vésiculaires (VGluT2), GLS et immunoréactivité au glutamate (IR) causée par une intervention chirurgicale dans un modèle post-incisionnel[7,8].
References:
[1]. Willis RC, Seegmiller JE. The inhibition by 6-diazo-5-oxo-l-norleucine of glutamine catabolism of the cultured human lymphoblast. J Cell Physiol. 1977 Dec;93(3):375-82. doi: 10.1002/jcp.1040930308. PMID: 22551.
[2]. Thangavelu K, Pan CQ, et,al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc Natl Acad Sci U S A. 2012 May 15;109(20):7705-10. doi: 10.1073/pnas.1116573109. Epub 2012 Apr 26. PMID: 22538822; PMCID: PMC3356676.
[3]. Rais R, Lemberg KM, et,al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv. 2022 Nov 18;8(46):eabq5925. doi: 10.1126/sciadv.abq5925. Epub 2022 Nov 16. PMID: 36383674; PMCID: PMC9668306.
[4]. Leone RD, Zhao L, et,al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019 Nov 22;366(6468):1013-1021. doi: 10.1126/science.aav2588. Epub 2019 Nov 7. PMID: 31699883; PMCID: PMC7023461.
[5]. Sharma NS, Gupta VK, et,al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020 Jan 2;130(1):451-465. doi: 10.1172/JCI127515. PMID: 31613799; PMCID: PMC6934212.
[6]. Sharma NS, Gupta VK, et,al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020 Jan 2;130(1):451-465. doi: 10.1172/JCI127515. PMID: 31613799; PMCID: PMC6934212.
[7]. Crosby HA, Miller KE. Evaluating the Analgesic Effect of the GLS Inhibitor 6-Diazo-5-Oxo-L-Norleucine in Vivo. Pharm Pharmacol Int J. 2016;3(3):00055. doi: 10.15406/ppij.2015.03.00055. Epub 2016 Jan 8. PMID: 29888760; PMCID: PMC5993434.
[8]. Miller KE, Hoffman EM, et,al. Glutamate pharmacology and metabolism in peripheral primary afferents: physiological and pathophysiological mechanisms. Pharmacol Ther. 2011 Jun;130(3):283-309. doi: 10.1016/j.pharmthera.2011.01.005. Epub 2011 Jan 26. PMID: 21276816; PMCID: PMC5937940.
Cas No. | 157-03-9 | SDF | |
Synonymes | DON, NSC 7365 | ||
Chemical Name | 6-diazo-5-oxo-L-norleucine | ||
Canonical SMILES | OC([C@@H](N)CCC(C=[N+]=[N-])=O)=O | ||
Formula | C6H9N3O3 | M.Wt | 171.2 |
Solubility | >1mg/mL in DMSO, >10mg/mL in Water(Need warm the tube at 50 ℃ and shake it in the ultrasonic bath for a while) | Storage | Store at -20°C,protect from light, stored under nitrogen |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 5.8411 mL | 29.2056 mL | 58.4112 mL |
5 mM | 1.1682 mL | 5.8411 mL | 11.6822 mL |
10 mM | 0.5841 mL | 2.9206 mL | 5.8411 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 20 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *